molecule in both adult and neonatal sera, with association constants of 7.0 x 104 and 1.3 x 104 M-1, respectively. These parameters were also derived for cefuroxime in adult serum and were 0.15 and 7.1 x 104 M-1, respectively. In neonatal serum, the combined value (number of binding sites per molecule x equilibrium association constant) was similar to combined values calculated for class 2 binding sites for cefuroxime in adult serum and for cefonicid in neonatal serum (287 versus 195 and 261 M-1, respectively). Cephalosporins have been shown to compete with bilirubin for albumin binding sites. Lower levels of protein binding of cefuroxime in the therapeutic range may mean a lower potential for drug displacement of bilirubin in neonates, on the basis of these results. It may be prudent to select less highly protein-bound agents when treating neonatal infections.
Serum protein binding significantly affects the pharmacokinetic and pharmacodynamic behaviors of drugs. Many drugs bind in vivo to serum proteins, usually albumin, forming a reversible complex through hydrogen bonding (18) . The proportion of bound drug depends on a number of factors, including drug and protein concentrations, the affinity of protein for the drug, and the number of protein binding sites (20) . Generally, only unbound drug is pharmacologically active (21) ; therefore, changes in serum protein binding can have important effects on clinical outcome.
Protein binding can determine the distribution, tissue penetration, clearance, and other pharmacokinetic properties of drugs (6, 7, 10, 15) . Interactions due to protein binding may become significant when two or more highly bound (>90%) agents with a common binding site are combined (10, 12) . The displacement that occurs from competition for binding sites results in elevated free concentrations of one or both drugs (12) , resulting in increased pharmacological effects or toxicities, increased tissue distribution, increased clearance, or a combination of these.
Displacement interactions may occur between drugs and protein-bound endogenous substances, such as bilirubin, resulting in increased free bilirubin concentrations (4, 11, 16) . Such a result is of particular importance in neonates, in whom the albumin concentration and binding affinity of albumin for bilirubin are already lower than those in adults (14) . A further reduction in bilirubin binding by competition for binding sites, resulting in increased levels of unbound bilirubin, will increase bilirubin penetration into the central nervous system and may lead to the development of kernicterus. In adults, the levels of plasma protein binding of cefonicid and cefuroxime have been reported to be 96 and 33%, respectively, at therapeutic concentrations (8, 9) .
However, the effect of various drug concentrations on serum protein binding and differences in the levels of protein binding of these antibiotics between adult and neonatal patients have not been well studied. Before we can fully investigate antibiotic displacement of bilirubin in neonates, we need to understand better the binding characteristics of these agents in adult and neonatal sera.
The objectives of this study were (i) to determine the effects of various drug concentrations on the protein binding of cefonicid and cefuroxime in pooled adult and neonatal sera, (ii) 4) . The antibiotic concentrations in the buffer samples ranged from 2.5 to 5,000 ,ug/ml. Serum samples were prepared with 2 ml of pooled serum, and aliquots of the drug stock solutions were added to obtain final antibiotic concentrations ranging from 25 to 3,000 ,ug/ml. High antibiotic concentrations were used to better characterize the binding of the drugs to serum proteins. Limitations in assay sensitivity prohibited the assessment of protein binding at lower drug concentrations. After incubation at room temperature for 30 min, free cefonicid and cefuroxime were separated from protein-bound drug by use of an ultrafiltration system with YMT filters (Amicon, Danvers, Mass.). One milliliter of spiked serum at each concentration was placed in the ultrafiltration system and centrifuged (Centra 4; International Equipment Co., Needham Heights, Mass.) at 3,000 rpm for 6 min, and the ultrafiltrate, containing free drug, was collected. All assays were done in duplicate.
Drug analysis. Concentrations of cefuroxime and cefonicid were assayed by previously published HPLC techniques (3, 5) . For cefuroxime, a 0.1 M acetate buffer (pH 3.85)-acetonitrile (90%:10%) mobile phase was used with 8-chlorotheophylline as the internal standard. For cefonicid, the mobile phase consisted of a 0.05 M phosphate buffer (pH 7.2)-methanol-acetonitrile (86%:6%:8%) mixture, and cefazolin was used as the internal standard. Mobile phases were delivered at a rate of 1.5 ml/min. HPLC analyses were performed with a Waters 510 pump, a WISP 710B sample processor, and a Lambda-Max model 481 (Waters, Milford, Mass.) variable-wavelength UV-visible light absorbance detector set at 254 nm. The analytical column used was a reversed-phase (C18) column (250 by 4.6 mm; particle size, 5 ,um) (Econosphere; Alltech Associates, Deerfield, Ill.).
The standard curves were linear in the antibiotic concentration range of 0.5 to 5,000 ,ug/ml for cefonicid and 1 to 5,000 ,ug/ml for cefuroxime. The lower limits of quantitation for the assay were 0.5 ,ug/ml for cefonicid and 1 ,ug/ml for cefuroxime. The intra-and interday coefficients of variation for the assays were less than 10% for both drugs at all drug concentrations measured. (4) and the protein binding parameter NK was estimated by nonlinear least-squares regression (13) with equations 3 and 4.
RESULTS
The fraction of cefonicid bound to serum proteins as a function of total drug concentration in adult and neonatal sera is illustrated in Fig. 1 roxime, in adult and neonatal sera. Cefonicid has been reported to be highly bound to serum proteins (8) , while cefuroxime has been reported to be moderately bound (9) . However, few investigations have examined the serum protein binding of drugs in the neonatal population. The protein binding of the antibiotics was studied over a wide range of drug concentrations, including those exceeding therapeutic levels, to accurately characterize and determine protein binding parameters. The results of this study demonstrate notable differences between the binding of these two cephalosporins in adult and neonatal sera.
The binding of cefonicid to both adult and neonatal serum proteins was highly dependent on drug concentration, with a decreased fraction of cefonicid being bound as drug concentration increased. Over the cefonicid concentration range of 25 to 3,000 ,g/ml, the percentage of drug bound to serum proteins decreased from 99.9 to 31.5% and from 90.0 to 20.9% in adult and neonatal sera, respectively. Within the therapeutic range, binding was independent of drug concentration at lower concentrations (25 to 150 ,ug/ml) but became nonlinear at higher concentrations (150 to 300 ,ug/ml, Fig. 1 ). Cefonicid protein binding in adult serum within the therapeutic range was similar to that reported previously (90 to 98%) (1, 8) . Cefonicid was found to bind to a high-affinity, saturable binding site as well as to a low-affinity site that was not saturated over the range of drug concentrations studied. Previous investigations suggested that cephalosporins associate with a single high-affinity binding site on serum albumin (19) . The results of the present study examining the binding of cefonicid support these earlier findings. However, a second class of low-affinity binding site was also detected. This second class of binding site was observed in the present study because of the wide range of drug concentrations used.
The fraction of cefonicid bound to neonatal serum proteins was smaller than that bound to adult serum proteins at all drug concentrations studied. This difference was relatively constant, with the fraction bound in neonatal serum being approximately 0.1 lower than that in adult serum. We attribute the lower level of fractional binding of cefonicid in neonatal serum to the 20% lower serum albumin concentration and the 80% lower equilibrium association constant in neonatal serum. The lower association constant in neonatal serum may be due to conformational differences between neonatal and adult albumin. Alternatively, the lower association constant may result from the presence of endogenous compounds, such as 2-hydroxybenzoylglycine, that competitively inhibit cefonicid binding to this class of binding site in neonatal serum and that are not present or are present in lower concentrations in adult serum (22 (16) . The risk of a clinically significant interaction occurring between cefonicid and bilirubin in neonates appears high. In contrast, cefuroxime showed no saturation of protein binding sites at the concentrations studied and would not therefore be expected to displace bilirubin significantly. The latter finding has been confirmed by others (16) . When a decision regarding the appropriate antibiotic choice in neonatal infections must be made, it may be prudent to choose an agent that is less extensively bound to albumin.
